All In Biotech

Drug Trial Radar · NCT01659021

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

261

Actual

Start

Dec 4, 2012

Primary completion

Aug 15, 2018

Study completion Aug 15, 2018

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • IdelalisibDrug

    150 mg tablets administered orally twice daily

  • OfatumumabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: Randomization to End of Study (up to 60 months)

Locations

80 sites in 11 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • California Cancer Associates for Research and Excellence (CCARE)

    Fresno, California

  • Kaiser Permanente

    San Diego, California

  • Coastal Integrative Cancer Care

    San Luis Obispo, California

  • Stanford University Medical Center

    Stanford, California

  • Kaiser Permanente Vallejo Medical Center

    Vallejo, California

  • Kaiser Permanente of Colorado

    Denver, Colorado

  • Saint Mary's Regional Cancer Center

    Grand Junction, Colorado

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Georgia Regents University

    Augusta, Georgia

  • Montgomery Cancer Center

    Mount Sterling, Kentucky

  • Center for Cancer and Blood Disorders, PC

    Bethesda, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Washington University Medical Center

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Weill Cornell Medical Center

    New York, New York

  • Oncology Hematology Care, Inc.

    Cincinnati, Ohio

  • The Ohio State University Medical Center

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Upstate Oncology Associates

    Greenville, South Carolina

  • Tennessee Oncology, PLLC

    Chattanooga, Tennessee

  • Tenessee Oncology, PLLC

    Nashville, Tennessee

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Northwest Medical Specialties

    Tacoma, Washington

  • Queen Elizabeth Hospital

    Woodville, Australia

  • Saint George and Sutherland Hospitals

    Kogarah, New South Wales, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Haematology and Oncology Clinics of Australia at Mater

    Milton, Queensland, Australia

  • Ashford Cancer Centre Research

    Ashford, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Frankston Hospital

    Melbourne, Victoria, Australia

  • Ziekenhuis Netwerk Antwerpen

    Antwerp, Belgium

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitaire Ziekenhuis Gasthuisberg

    Leuven, Belgium

  • Cancer Care Manitoba

    Winnipeg, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.